Hos cancerpatienter var den farmakokinetiske profil af Biograstim og referenceproduktet sammenlignelige efter en enkelt og gentagne subkutane doser.
In cancer patients, the pharmacokinetic profile of Biograstim and the reference product was comparable after single and repeated subcutaneous administration.